Patents by Inventor Olivier Dhellin

Olivier Dhellin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR TREATING IFNALPHA RELATED CONDITIONS
    Publication number: 20180207288
    Abstract: An immunogenic product including IFN? coupled to a carrier protein molecule is capable to induce in vivo anti-IFN? antibodies and is useful in treating IFN? related conditions.
    Type: Application
    Filed: March 26, 2018
    Publication date: July 26, 2018
    Inventors: Geraldine GROUARD-VOGEL, Olivier DHELLIN, Bernard FANGET, Pierre VANDEPAPELIERE, Camille ROUCAIROL
  • Method for treating IFNalpha related conditions
    Patent number: 9993565
    Abstract: An immunogenic product including IFN? coupled to a carrier protein molecule is capable to induce in vivo anti-IFN? antibodies and is useful in treating IFN? related conditions.
    Type: Grant
    Filed: April 4, 2012
    Date of Patent: June 12, 2018
    Assignee: NEOVACS
    Inventors: Geraldine Grouard-Vogel, Olivier Dhellin, Bernard Fanget, Pierre Vandepapeliere, Camille Roucairol
  • METHOD FOR TREATING IFNALPHA RELATED CONDITIONS
    Publication number: 20140023617
    Abstract: An immunogenic product including IFN? coupled to a carrier protein molecule is capable to induce in vivo anti-IFN? antibodies and is useful in treating IFN? related conditions.
    Type: Application
    Filed: April 4, 2012
    Publication date: January 23, 2014
    Applicant: NEOVACS
    Inventors: Geraldine Grouard-Vogel, Olivier Dhellin, Bernard Fanget, Pierre Vandepapeliere, Camille Roucairol
  • STRONGLY INACTIVATED AND STILL HIGHLY IMMUNOGENIC VACCINE AND PROCESS OF MANUFACTURING THEREOF
    Publication number: 20130259892
    Abstract: An immunogenic product includes TNF? coupled with KLH, wherein the TNF? is strongly inactivated, which means that the product shows less than 30% of cytolytic activity and/or an inactivation factor of more than 15000, in the conditions of TEST A. An emulsion and a vaccine including the product and methods for preparing the immunogenic product are also described.
    Type: Application
    Filed: December 8, 2011
    Publication date: October 3, 2013
    Inventors: Geraldine Grouard-Vogel, Olivier Dhellin, Bernard Fancet, Pierre Vandepapeliere
  • STRONGLY INACTIVATED AND STILL HIGHLY IMMUNOGENIC VACCINE AND PROCESS OF MANUFACTURING THEREOF
    Publication number: 20120148526
    Abstract: An immunogenic product includes TNF? coupled with KLH, wherein the TNF? is strongly inactivated, which means that the product shows less than 30% of cytolytic activity and/or an inactivation factor of more than 15000, in the conditions of TEST A. An emulsion and a vaccine including the immunogenic product and methods for preparing the immunogenic product are also described.
    Type: Application
    Filed: December 8, 2010
    Publication date: June 14, 2012
    Applicant: NEOVACS
    Inventors: Géraldine GROUARD-VOGEL, Olivier DHELLIN, Bernard FANGET, Pierre VANDEPAPELIÈRE
  • Method for preparing membrane vesicles
    Patent number: 6899863
    Abstract: This invention relates to a method of preparing membrane vesicles from a biological sample, characterised in that it comprises at least one anion exchange and/or gel permeation chromatography treatment of the sample. The invention is used to prepare vesicles of varied origins and types, particularly from antigen presenting cells or tumoral cells. The invention also relates to the vesicles obtained in this way and their uses.
    Type: Grant
    Filed: January 19, 2000
    Date of Patent: May 31, 2005
    Inventors: Olivier Dhellin, Sebastian Amigorena, Philippe Rameau, Joël Crouzet